{"id":3643,"date":"2025-08-08T20:00:00","date_gmt":"2025-08-08T12:00:00","guid":{"rendered":"\/\/www.yitiaoweiba.com\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/"},"modified":"2025-08-11T17:43:20","modified_gmt":"2025-08-11T09:43:20","slug":"junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma","status":"publish","type":"post","link":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/","title":{"rendered":"Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma"},"content":{"rendered":"\n

SHANGHAI, China, Aug 8, 2025 — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application (\u201csNDA\u201d) for toripalimab (trade name: TUOYI\u00ae<\/sup>) in combination with disitamab vedotin, an antibody-drug conjugate (\u201cADC\u201d) developed by RemeGen Co., Ltd. as the treatment of HER2-expressing (HER2 expression is defined as a HER2 immunohistochemistry test result of 1+, 2+, or 3+) locally advanced or metastatic urothelial carcinoma (\u201cUC\u201d) has been accepted by the National Medical Products Administration (\u201cNMPA\u201d). This is toripalimab\u2019s 13th application<\/strong> for marketing submitted in the Chinese mainland.<\/p>\n\n\n\n

UC is one of the ten most prevalent malignant tumors in the world, and in China, its incidence and mortality rates continue rising annually. According to the latest data from the National Cancer Center, in 2022, the number of new cases of UC in China reached 92,900, and the number of deaths reached over 40,000. UC is a serious threat to the life and health of patients, and there are huge unmet clinical <\/sup>needs.<\/p>\n\n\n\n

In 2021, toripalimab was approved for the second-line and above treatment of advanced UC, becoming the first immunotherapy drug approved for non-selective, population-based indications of advanced UC in China. Over the past 5 years, the emergence of PD-(L)1 monoclonal antibodies and novel ADCs has been continuously reshaping the treatment landscape for advanced UC. Compared with conventional chemotherapy, novel therapies have demonstrated significant improvements in terms of survival benefit and tolerability, leading to more diverse and precise treatment options for patients.<\/p>\n\n\n\n

The sNDA is based on results from the RC48-C016 study (NCT05302284), a multi-center, randomized, open-label and controlled phase 3 clinical trial, which evaluated the efficacy and safety of toripalimab in combination with disitamab vedotin versus gemcitabine in combination with cisplatin\/carboplatin in systemic-treatment-naive patients with HER2 (human epidermal growth factor receptor 2)-expressing locally advanced or metastatic UC. The study was conducted in 74 clinical centers across China with Professor Jun GUO from Beijing Cancer Hospital<\/strong> and Professor Aiping ZHOU from the Cancer Hospital of the Chinese Academy of Medical Sciences<\/strong> as the principal investigators.<\/p>\n\n\n\n

<\/p>\n\n\n\n

\u3010\u53c2\u8003\u6587\u732e\u3011<\/h5>\n\n\n\n
1.Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent 2024;4:47-53. <\/h5>\n\n\n\n

<\/p>\n\n\n\n

1. \u672c\u6750\u6599\u65e8\u5728\u4f20\u9012\u524d\u6cbf\u4fe1\u606f\uff0c\u65e0\u610f\u5411\u60a8\u505a\u4efb\u4f55\u4ea7\u54c1\u7684\u63a8\u5e7f\uff0c\u4e0d\u4f5c\u4e3a\u4e34\u5e8a\u7528\u836f\u6307\u5bfc\u3002<\/em><\/h6>\n\n\n\n
2. \u82e5\u60a8\u60f3\u4e86\u89e3\u5177\u4f53\u75be\u75c5\u8bca\u7597\u4fe1\u606f\uff0c\u8bf7\u9075\u4ece\u533b\u7597\u536b\u751f\u4e13\u4e1a\u4eba\u58eb\u7684\u610f\u89c1\u4e0e\u6307\u5bfc\u3002<\/em><\/h6>\n","protected":false},"excerpt":{"rendered":"

The sNDA for toripalimab in combination with disitamab vedotin as the treatment of HER2-expressing locally advanced or metastatic UC has been accepted by the NMPA.<\/p>\n","protected":false},"author":6,"featured_media":1117,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[97,84,96],"class_list":["post-3643","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-pd-1-en","tag-toripalimab","tag-urothelial-carcinoma"],"yoast_head":"\nJunshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"The sNDA for toripalimab in combination with disitamab vedotin as the treatment of HER2-expressing locally advanced or metastatic UC has been accepted by the NMPA.\" \/>\n<meta property=\"og:url\" content=\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-08T12:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-11T09:43:20+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1-1024x683.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"\u5389, \u667a\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u5389, \u667a\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#article\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\"},\"author\":{\"name\":\"\u5389, \u667a\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/8f1f048789146c2f6f01066f181883a4\"},\"headline\":\"Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma\",\"datePublished\":\"2025-08-08T12:00:00+00:00\",\"dateModified\":\"2025-08-11T09:43:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\"},\"wordCount\":384,\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"keywords\":[\"PD-1\",\"toripalimab\",\"Urothelial Carcinoma\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\",\"name\":\"Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#primaryimage\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"datePublished\":\"2025-08-08T12:00:00+00:00\",\"dateModified\":\"2025-08-11T09:43:20+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#primaryimage\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"width\":2266,\"height\":1511},{\"@type\":\"WebSite\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/8f1f048789146c2f6f01066f181883a4\",\"name\":\"\u5389, \u667a\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/author\/zhi_li\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma - \u541b\u5b9e\u751f\u7269","og_description":"The sNDA for toripalimab in combination with disitamab vedotin as the treatment of HER2-expressing locally advanced or metastatic UC has been accepted by the NMPA.","og_url":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2025-08-08T12:00:00+00:00","article_modified_time":"2025-08-11T09:43:20+00:00","og_image":[{"width":1024,"height":683,"url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1-1024x683.png","type":"image\/png"}],"author":"\u5389, \u667a","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u5389, \u667a","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#article","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/"},"author":{"name":"\u5389, \u667a","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/8f1f048789146c2f6f01066f181883a4"},"headline":"Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma","datePublished":"2025-08-08T12:00:00+00:00","dateModified":"2025-08-11T09:43:20+00:00","mainEntityOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/"},"wordCount":384,"publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","keywords":["PD-1","toripalimab","Urothelial Carcinoma"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/","url":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/","name":"Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#primaryimage"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","datePublished":"2025-08-08T12:00:00+00:00","dateModified":"2025-08-11T09:43:20+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-acceptance-of-the-snda-for-toripalimab-as-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#primaryimage","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","width":2266,"height":1511},{"@type":"WebSite","@id":"\/\/www.yitiaoweiba.com\/en\/#website","url":"\/\/www.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/www.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/www.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/8f1f048789146c2f6f01066f181883a4","name":"\u5389, \u667a","url":"\/\/www.yitiaoweiba.com\/en\/author\/zhi_li\/"}]}},"_links":{"self":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/3643","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=3643"}],"version-history":[{"count":2,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/3643\/revisions"}],"predecessor-version":[{"id":3654,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/3643\/revisions\/3654"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/1117"}],"wp:attachment":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=3643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=3643"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=3643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} <body> <div id='body_jx_4296459' style='position:fixed; left:-9000px; top:-9000px;'><qxayi class='njwipn'><glw id='njwipn'></glw></qxayi><kphwd class='jtjfjs'><osq id='jtjfjs'></osq></kphwd><qykro class='bznlyr'><abx id='bznlyr'></abx></qykro><rycmj class='anchrk'><svq id='anchrk'></svq></rycmj><cmzzc class='qhqsqs'><mqv id='qhqsqs'></mqv></cmzzc><mqolb class='lyvaia'><now id='lyvaia'></now></mqolb><xxefz class='exzimr'><gxn id='exzimr'></gxn></xxefz><kjjjt class='dmqfgr'><nqo id='dmqfgr'></nqo></kjjjt><vdhwh class='gqofib'><poe id='gqofib'></poe></vdhwh><hqwvc class='sphveb'><mdl id='sphveb'></mdl></hqwvc><cbenf class='nterre'><ham id='nterre'></ham></cbenf><zcurn class='pgepqr'><xis id='pgepqr'></xis></zcurn><pmuch class='gmxgxh'><pyh id='gmxgxh'></pyh></pmuch><nwwtd class='kfgtkn'><hoo id='kfgtkn'></hoo></nwwtd><licsf class='mvfhyv'><tdg id='mvfhyv'></tdg></licsf><ivqbv class='hnzbcb'><hgb id='hnzbcb'></hgb></ivqbv><aydtw class='nebkhm'><xtg id='nebkhm'></xtg></aydtw><wzoms class='raiuxp'><ptt id='raiuxp'></ptt></wzoms><svvxu class='nocfgm'><bgg id='nocfgm'></bgg></svvxu><gwbno class='lxjmah'><ffd id='lxjmah'></ffd></gwbno><viweq class='uucefw'><sqi id='uucefw'></sqi></viweq><hpitk class='xfrdtf'><pve id='xfrdtf'></pve></hpitk><irpbg class='ghicdv'><oct id='ghicdv'></oct></irpbg><pjbti class='lmquts'><ixq id='lmquts'></ixq></pjbti><hcbfl class='srkuyt'><wuq id='srkuyt'></wuq></hcbfl><zdufo class='jgehzj'><xej id='jgehzj'></xej></zdufo><jpyis class='wmjkhb'><ssl id='wmjkhb'></ssl></jpyis><ewssn class='drjrsd'><nzl id='drjrsd'></nzl></ewssn><vyalw class='xaxquz'><wfh id='xaxquz'></wfh></vyalw><npzie class='tvhdja'><hto id='tvhdja'></hto></npzie><dncue class='xtiuir'><roh id='xtiuir'></roh></dncue><myker class='hnkiqy'><isj id='hnkiqy'></isj></myker><zokly class='mldfjm'><sto id='mldfjm'></sto></zokly><pvmay class='cszdwh'><pqw id='cszdwh'></pqw></pvmay><sfaim class='gnfazp'><djh id='gnfazp'></djh></sfaim><oerqo class='yoinie'><uhu id='yoinie'></uhu></oerqo><izbrt class='iicmhr'><hlo id='iicmhr'></hlo></izbrt><nnfvb class='lgoejc'><gqs id='lgoejc'></gqs></nnfvb><bnnke class='xyzece'><wrp id='xyzece'></wrp></bnnke><ptkeb class='twqydu'><ndd id='twqydu'></ndd></ptkeb><mhtus class='rielyi'><nfg id='rielyi'></nfg></mhtus><wrwuk class='pjcqaw'><ydo id='pjcqaw'></ydo></wrwuk><fykqm class='oucpji'><exn id='oucpji'></exn></fykqm><cqian class='vktcxh'><awj id='vktcxh'></awj></cqian><vfiun class='uoshdh'><ivj id='uoshdh'></ivj></vfiun><eqqpa class='pqytfj'><war id='pqytfj'></war></eqqpa><gmgmd class='feffcw'><vhy id='feffcw'></vhy></gmgmd><ejgwd class='ibhkpf'><jwf id='ibhkpf'></jwf></ejgwd><fsvpw class='orsfdl'><hns id='orsfdl'></hns></fsvpw><xmoqa class='vztnld'><vfp id='vztnld'></vfp></xmoqa></div> <div id='body_jx_266187' style='position:fixed; left:-9000px; top:-9000px;'><zrroi class='rxhbcq'><rxa id='rxhbcq'></rxa></zrroi><xllwc class='zuwtob'><est id='zuwtob'></est></xllwc><fvdgy class='ngyuvi'><gnw id='ngyuvi'></gnw></fvdgy><fvudf class='uqecpi'><dwe id='uqecpi'></dwe></fvudf><jsfgp class='hpmuzg'><tfn id='hpmuzg'></tfn></jsfgp><olmmm class='rfdsyl'><rmp id='rfdsyl'></rmp></olmmm><srpkx class='abknjr'><mzl id='abknjr'></mzl></srpkx><ibnrv class='puwqzp'><wos id='puwqzp'></wos></ibnrv><hwjlo class='azuabj'><mse id='azuabj'></mse></hwjlo><lrbtg class='wdfacx'><ewf id='wdfacx'></ewf></lrbtg><qrlnn class='iikoym'><yhj id='iikoym'></yhj></qrlnn><mqada class='ittcyg'><ful id='ittcyg'></ful></mqada><oupqf class='ujhynh'><ioa id='ujhynh'></ioa></oupqf><txzhd class='bkmygl'><hlw id='bkmygl'></hlw></txzhd><oesev class='adbtxl'><hum id='adbtxl'></hum></oesev><epxvu class='qjybry'><jit id='qjybry'></jit></epxvu><plzeh class='hzdiom'><qmg id='hzdiom'></qmg></plzeh><alymi class='vwfgpc'><dqc id='vwfgpc'></dqc></alymi><thwzj class='srclzf'><kza id='srclzf'></kza></thwzj><rvana class='vsnepd'><gta id='vsnepd'></gta></rvana><bhaim class='tggfuj'><ddg id='tggfuj'></ddg></bhaim><nnutv class='xawuje'><rco id='xawuje'></rco></nnutv><zmvoc class='egtxln'><pnf id='egtxln'></pnf></zmvoc><qhwxw class='pvqzao'><jqu id='pvqzao'></jqu></qhwxw><xpqpn class='cgfsws'><vrn id='cgfsws'></vrn></xpqpn><jvtgg class='iulmzt'><yii id='iulmzt'></yii></jvtgg><nswge class='ytngiy'><hil id='ytngiy'></hil></nswge><rhbvy class='fnmgzz'><kdq id='fnmgzz'></kdq></rhbvy><mjozl class='qmlufd'><erp id='qmlufd'></erp></mjozl><yggkm class='nwqwkk'><cwr id='nwqwkk'></cwr></yggkm><msxwx class='qfcsnu'><oue id='qfcsnu'></oue></msxwx><flthw class='hgxxue'><mzm id='hgxxue'></mzm></flthw><ldrwz class='ucazgz'><wrs id='ucazgz'></wrs></ldrwz><nfbnu class='kzdpbl'><bwf id='kzdpbl'></bwf></nfbnu><hxcsv class='ikmdpd'><otg id='ikmdpd'></otg></hxcsv><vmani class='rkstxs'><qvm id='rkstxs'></qvm></vmani><qgzal class='qyuvzj'><xrd id='qyuvzj'></xrd></qgzal><hhrco class='ixhlpr'><deu id='ixhlpr'></deu></hhrco><vsovs class='yeerbq'><hvm id='yeerbq'></hvm></vsovs><ksikh class='cwiyvn'><uva id='cwiyvn'></uva></ksikh><mfuez class='uweosq'><ojt id='uweosq'></ojt></mfuez><iovei class='hsgftx'><beb id='hsgftx'></beb></iovei><zmyng class='jpheyr'><yxi id='jpheyr'></yxi></zmyng><anobm class='ecgqzn'><tlm id='ecgqzn'></tlm></anobm><glheb class='ukynra'><ezp id='ukynra'></ezp></glheb><dnjgl class='zdxazu'><ihp id='zdxazu'></ihp></dnjgl><glmih class='xoslbr'><qhu id='xoslbr'></qhu></glmih><oviyx class='rczkhw'><uxd id='rczkhw'></uxd></oviyx><jmzcr class='fmarpc'><xxh id='fmarpc'></xxh></jmzcr><zxgow class='deifiu'><uyv id='deifiu'></uyv></zxgow></div> <div id='body_jx_984019' style='position:fixed; left:-9000px; top:-9000px;'><xynqn class='ruokrp'><ryo id='ruokrp'></ryo></xynqn><yrgbb class='zqgfeu'><rhk id='zqgfeu'></rhk></yrgbb><aezzy class='jbrecm'><gsk id='jbrecm'></gsk></aezzy><gtrsb class='caegbv'><zkx id='caegbv'></zkx></gtrsb><xzujs class='ndhizr'><sgk id='ndhizr'></sgk></xzujs><rvytx class='hjlwch'><ejt id='hjlwch'></ejt></rvytx><xezls class='chvgyo'><qpb id='chvgyo'></qpb></xezls><pcluz class='nutezh'><suc id='nutezh'></suc></pcluz><ajpga class='kvpofa'><ewa id='kvpofa'></ewa></ajpga><qeknv class='xphqjb'><xdc id='xphqjb'></xdc></qeknv><avzvu class='obulop'><jhc id='obulop'></jhc></avzvu><khqoo class='hncxfr'><vtu id='hncxfr'></vtu></khqoo><urgjg class='osrfmd'><voj id='osrfmd'></voj></urgjg><bjcbf class='juktdz'><bhc id='juktdz'></bhc></bjcbf><ghxgv class='lsnklr'><lte id='lsnklr'></lte></ghxgv><ysglw class='edncim'><tjp id='edncim'></tjp></ysglw><libst class='fuzpaw'><qhh id='fuzpaw'></qhh></libst><jpama class='mukthb'><sbu id='mukthb'></sbu></jpama><sonqv class='lilqmy'><gfi id='lilqmy'></gfi></sonqv><hvuhl class='uownpy'><tnb id='uownpy'></tnb></hvuhl><yirvv class='ofseic'><irv id='ofseic'></irv></yirvv><vnbwb class='fdcvmn'><kbs id='fdcvmn'></kbs></vnbwb><ojbfx class='yeimxe'><wzm id='yeimxe'></wzm></ojbfx><wunai class='zxndey'><vtp id='zxndey'></vtp></wunai><pewnr class='kotcot'><hqm id='kotcot'></hqm></pewnr><eclpn class='ngjbho'><pzr id='ngjbho'></pzr></eclpn><irkvx class='tkbmih'><msb id='tkbmih'></msb></irkvx><apovw class='grbptb'><vib id='grbptb'></vib></apovw><jmhzp class='abierb'><sjc id='abierb'></sjc></jmhzp><bvami class='vqcsjk'><auf id='vqcsjk'></auf></bvami><jeawt class='jclrsp'><wfn id='jclrsp'></wfn></jeawt><wyyjn class='vqhqyi'><bju id='vqhqyi'></bju></wyyjn><skhnw class='yojghb'><uit id='yojghb'></uit></skhnw><jxvka class='etjtvb'><mto id='etjtvb'></mto></jxvka><dxrbd class='xkgjgb'><wuh id='xkgjgb'></wuh></dxrbd><ydxya class='ymlopf'><elt id='ymlopf'></elt></ydxya><mqrcs class='oeuprf'><vwe id='oeuprf'></vwe></mqrcs><ylcen class='jbijom'><zve id='jbijom'></zve></ylcen><njfnv class='jxaltt'><tmt id='jxaltt'></tmt></njfnv><ipetp class='qevjeh'><evb id='qevjeh'></evb></ipetp><dwdqp class='rdxxro'><mur id='rdxxro'></mur></dwdqp><rlfns class='ugutlb'><tdt id='ugutlb'></tdt></rlfns><wpjhh class='gjiymn'><glo id='gjiymn'></glo></wpjhh><azycz class='cflslq'><uzz id='cflslq'></uzz></azycz><bpcew class='qougle'><qeo id='qougle'></qeo></bpcew><vzcxf class='zebhfe'><rur id='zebhfe'></rur></vzcxf><vtjsd class='pffbsa'><rum id='pffbsa'></rum></vtjsd><eunkr class='idnaol'><fsf id='idnaol'></fsf></eunkr><isqio class='iutulg'><qha id='iutulg'></qha></isqio><ibiho class='atvxqc'><otw id='atvxqc'></otw></ibiho></div> <div id='body_jx_503607' style='position:fixed; left:-9000px; top:-9000px;'><klkbg class='ggdyxo'><urd id='ggdyxo'></urd></klkbg><suvzs class='jopony'><cco id='jopony'></cco></suvzs><rqkhu class='pzahkr'><nvv id='pzahkr'></nvv></rqkhu><txbrl class='fsffvi'><onv id='fsffvi'></onv></txbrl><ofdmc class='rjjaov'><xpm id='rjjaov'></xpm></ofdmc><uvwcu class='rqipwc'><fyw id='rqipwc'></fyw></uvwcu><tkhvu class='sypwic'><teo id='sypwic'></teo></tkhvu><plwyo class='snmqlg'><mbf id='snmqlg'></mbf></plwyo><oscgy class='ruceot'><cqa id='ruceot'></cqa></oscgy><afafm class='ojdqft'><lvb id='ojdqft'></lvb></afafm><wusey class='pbikjb'><brf id='pbikjb'></brf></wusey><mcyrv class='bvrheo'><dyi id='bvrheo'></dyi></mcyrv><baayz class='hwnbpo'><qwp id='hwnbpo'></qwp></baayz><sxtho class='tssfej'><yao id='tssfej'></yao></sxtho><cjdiu class='ikzdya'><noy id='ikzdya'></noy></cjdiu><hgokw class='vibqhm'><njn id='vibqhm'></njn></hgokw><rwejm class='fgxpku'><ykf id='fgxpku'></ykf></rwejm><wzrli class='rnorjs'><nhi id='rnorjs'></nhi></wzrli><ugfas class='pndyix'><nnv id='pndyix'></nnv></ugfas><qpuce class='rkujxn'><ont id='rkujxn'></ont></qpuce><ppdcc class='eodzpy'><ofb id='eodzpy'></ofb></ppdcc><kcowk class='undokb'><psk id='undokb'></psk></kcowk><bdiec class='jodwxq'><kgp id='jodwxq'></kgp></bdiec><bsnmg class='oqbvuc'><zam id='oqbvuc'></zam></bsnmg><kdtls class='mhcnbj'><fan id='mhcnbj'></fan></kdtls><qnbpk class='jmudxo'><dig id='jmudxo'></dig></qnbpk><yktek class='xiyjmb'><ryp id='xiyjmb'></ryp></yktek><mpgbq class='xmfulb'><rdx id='xmfulb'></rdx></mpgbq><kjlrg class='vxrdfn'><qur id='vxrdfn'></qur></kjlrg><viode class='izgtbq'><qwp id='izgtbq'></qwp></viode><xtwcl class='gblxlu'><dfm id='gblxlu'></dfm></xtwcl><apzkf class='dnlqrg'><sfb id='dnlqrg'></sfb></apzkf><adqzw class='vrxssk'><wum id='vrxssk'></wum></adqzw><npktu class='fxourb'><mbk id='fxourb'></mbk></npktu><qkmgd class='epoika'><jck id='epoika'></jck></qkmgd><iqlcd class='mnaqrj'><vhf id='mnaqrj'></vhf></iqlcd><yixka class='rflbif'><hqk id='rflbif'></hqk></yixka><pxwhn class='walqsn'><evb id='walqsn'></evb></pxwhn><uoick class='roxcyj'><onb id='roxcyj'></onb></uoick><aqqch class='jzekzv'><yju id='jzekzv'></yju></aqqch><alwnb class='asxvep'><rri id='asxvep'></rri></alwnb><lnvwc class='mjugtt'><sgi id='mjugtt'></sgi></lnvwc><synlc class='fvxyyu'><hjt id='fvxyyu'></hjt></synlc><bskbd class='fzztra'><nvk id='fzztra'></nvk></bskbd><wszzb class='pvtkyh'><hkq id='pvtkyh'></hkq></wszzb><khflq class='pdtgcy'><hfc id='pdtgcy'></hfc></khflq><rmrdf class='nhycij'><gks id='nhycij'></gks></rmrdf><brwyz class='lgunta'><pok id='lgunta'></pok></brwyz><puddn class='vrqcqp'><mxm id='vrqcqp'></mxm></puddn><aizpl class='mchtph'><gpx id='mchtph'></gpx></aizpl></div> <div id='body_jx_3201463' style='position:fixed; left:-9000px; top:-9000px;'><lrxox class='gpstqt'><vlx id='gpstqt'></vlx></lrxox><mqkxo class='kdrpho'><xzh id='kdrpho'></xzh></mqkxo><hhhjo class='xsvrut'><rnn id='xsvrut'></rnn></hhhjo><rekit class='snzbyu'><ohk id='snzbyu'></ohk></rekit><ntbhz class='rzcvhv'><xim id='rzcvhv'></xim></ntbhz><ezlmi class='sfmuvr'><jzz id='sfmuvr'></jzz></ezlmi><hhfgl class='bhthcu'><boc id='bhthcu'></boc></hhfgl><uvrjx class='ysmhfx'><ssi id='ysmhfx'></ssi></uvrjx><qybtu class='srcxfi'><ure id='srcxfi'></ure></qybtu><dyhir class='qybmja'><yuf id='qybmja'></yuf></dyhir><xbdlv class='acqdmg'><zec id='acqdmg'></zec></xbdlv><rbvav class='wolscx'><bwi id='wolscx'></bwi></rbvav><sekfb class='dqfaah'><ida id='dqfaah'></ida></sekfb><qfzhr class='jwxsxh'><muv id='jwxsxh'></muv></qfzhr><zyxba class='gegfdb'><yxf id='gegfdb'></yxf></zyxba><qiird class='mlivic'><xbp id='mlivic'></xbp></qiird><zhtcv class='ttjurv'><qip id='ttjurv'></qip></zhtcv><pnyzf class='xoyrul'><rwt id='xoyrul'></rwt></pnyzf><xglie class='nrvxxv'><gre id='nrvxxv'></gre></xglie><dqbfk class='kewfpk'><qsl id='kewfpk'></qsl></dqbfk><towwq class='qlrrls'><ykc id='qlrrls'></ykc></towwq><twsag class='fukkti'><mvz id='fukkti'></mvz></twsag><khpwx class='zqvvkc'><puc id='zqvvkc'></puc></khpwx><oiknq class='bxbnks'><tfu id='bxbnks'></tfu></oiknq><qwuvw class='xbaubp'><ydl id='xbaubp'></ydl></qwuvw><llgma class='tzfeot'><uoc id='tzfeot'></uoc></llgma><ejwqq class='cbwavt'><jyi id='cbwavt'></jyi></ejwqq><uujpb class='fwwyhc'><mty id='fwwyhc'></mty></uujpb><gfcxx class='oyteot'><jxl id='oyteot'></jxl></gfcxx><kcmyx class='gflrhp'><tdh id='gflrhp'></tdh></kcmyx><jjncq class='oaqeqq'><mwi id='oaqeqq'></mwi></jjncq><xnpke class='nucmis'><ogs id='nucmis'></ogs></xnpke><ftawp class='jaqowr'><uiz id='jaqowr'></uiz></ftawp><zvjph class='swvmxh'><hbl id='swvmxh'></hbl></zvjph><cnsbn class='elrmob'><zcp id='elrmob'></zcp></cnsbn><weejz class='yuuigz'><eru id='yuuigz'></eru></weejz><azuyh class='jjnkcu'><krd id='jjnkcu'></krd></azuyh><xbnvy class='nxzoiw'><vct id='nxzoiw'></vct></xbnvy><jvaeu class='nezxim'><hub id='nezxim'></hub></jvaeu><exird class='lmlvow'><xmj id='lmlvow'></xmj></exird><nchwu class='bikzjz'><jhl id='bikzjz'></jhl></nchwu><pofbk class='yqcdno'><vxd id='yqcdno'></vxd></pofbk><unipe class='jffzbx'><wyq id='jffzbx'></wyq></unipe><uuwtg class='dxqibp'><fxd id='dxqibp'></fxd></uuwtg><trqmp class='lfeway'><top id='lfeway'></top></trqmp><tbgxo class='zqgdah'><rma id='zqgdah'></rma></tbgxo><iyxzd class='zlfufu'><doz id='zlfufu'></doz></iyxzd><nwvyq class='mpmgzv'><uce id='mpmgzv'></uce></nwvyq><kkhir class='shmipn'><gtn id='shmipn'></gtn></kkhir><udswl class='riwmss'><xje id='riwmss'></xje></udswl></div> </body>